[co-author: Vicky Vlontzou]
On 29 May 2020, the AFMPS issued a new decision which further extends the measures initially provided in the Decision 1 April 2020 concerning supply of specific medicinal products by another month. These measures were previously extended until 1 June 2020. The new Decision also provides for the relaxation of some of the measures that were previously imposed.
On 29 May 2020, the AFMPS issued a new Decision which further extends the measures initially provided in the Decision of 1 April 2020 on various urgent measures concerning specific medicinal products to combat shortages in the context of the SARS-CoV-2 pandemic, by another month. These measures, which had been previously revised on 8 April 2020, and extended until 1 June 2020 by the Decision of 28 April 2020, are now extended until 1 July 2020.
The new Decision abolishes the notification obligation for the supply of certain medicinal products and raw materials within and outside the European Economic Area (EEA).
The measures concerning quotas for wholesalers, optimal distribution among hospitals, and exports of medicinal products remain in place.
Stocks of medicinal products and raw materials intended to combat the symptoms of COVID-19 or to treat affected patients (such as anaesthetics and muscle relaxants) are still being closely monitored by the AFMPS despite the decrease in the number of infected patients and in light of the possibility of a resurgence of the coronavirus.
The list of medicinal products and raw materials concerned has also been revised.
[View source.]
